SAL067

DRUG3 trials

Sponsors

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Conditions

Diabetes Mellitus, Type 2Renal InsuficiencyType 2 Diabetes Mellitus (T2DM)

Phase 1

The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal Insufficiency

CompletedNCT06883656

Shenzhen Salubris Pharmaceuticals Co., Ltd.Renal Insuficiency, Type 2 Diabetes Mellitus (T2DM)

Start: 2022-03-15End: 2022-11-01Updated: 2025-03-19

Phase 3

SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

CompletedNCT05782192

Shenzhen Salubris Pharmaceuticals Co., Ltd.Diabetes Mellitus, Type 2

Start: 2019-06-13End: 2022-03-25Updated: 2023-03-23

SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin

CompletedNCT05801627

Shenzhen Salubris Pharmaceuticals Co., Ltd.Diabetes Mellitus, Type 2

Start: 2020-05-06End: 2022-05-24Updated: 2023-04-06

Related Papers

Pharmacokinetics, Pharmacodynamics and Safety of Fultagliptin Benzoate Tablets, a DPP-4 Inhibitor, in Patients With Varying Degrees of Renal Insufficiency and Matched Healthy Volunteers: A Phase I Clinical Trial.

2026-02-09

Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial.

2023-10-092 citations